Edition:
United Kingdom

Pfizer Inc (PFE.N)

PFE.N on New York Stock Exchange

42.40USD
15 Feb 2019
Change (% chg)

$0.43 (+1.02%)
Prev Close
$41.97
Open
$42.36
Day's High
$42.51
Day's Low
$42.08
Volume
6,267,335
Avg. Vol
7,964,533
52-wk High
$46.46
52-wk Low
$34.32

Chart for

About

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business... (more)

Overall

Beta: 0.99
Market Cap(Mil.): $214,682.30
Shares Outstanding(Mil.): 5,955.13
Dividend: 0.32
Yield (%): 3.55

Financials

  PFE.N Industry Sector
P/E (TTM): 26.26 30.48 33.70
EPS (TTM): 1.37 -- --
ROI: 6.00 14.95 14.45
ROE: 13.80 16.27 15.96

Merck, Pfizer drug combo extends kidney cancer survival: study

A combination of Merck & Co's immunotherapy Keytruda and Pfizer Inc's Inlyta helped patients with advanced kidney cancer live longer than those receiving and older Pfizer standalone therapy, according to data from a late-stage study presented on Saturday.

16 Feb 2019

Merck, Pfizer drug combo extends kidney cancer survival -study

Feb 16 A combination of Merck & Co's immunotherapy Keytruda and Pfizer Inc's Inlyta helped patients with advanced kidney cancer live longer than those receiving and older Pfizer standalone therapy, according to data from a late-stage study presented on Saturday.

16 Feb 2019

Merck, Pfizer combo treatment boosts kidney cancer survival

NEW YORK Drugmaker Merck & Co Inc said on Monday that the combination of its cancer immunotherapy Keytruda with Pfizer Inc's Inlyta cut the risk of death nearly in half for patients with the most common form of kidney cancer when compared with treatment with chemotherapy drug Sutent.

12 Feb 2019

Pfizer Japan recalls high blood pressure drug over cancer-causing impurity

TOKYO The Japanese subsidiary of Pfizer Inc is recalling a drug for high blood pressure which was found to contain a carcinogenic substance in its active ingredient valsartan, the drugmaker said on Friday.

09 Feb 2019

Pfizer Japan recalls high blood pressure drug over cancer-causing impurity

TOKYO The Japanese subsidiary of Pfizer Inc is recalling a drug for high blood pressure which was found to contain a carcinogenic substance in its active ingredient valsartan, the drugmaker said on Friday.

08 Feb 2019

UPDATE 1-Pfizer Japan recalls high blood pressure drug over cancer-causing impurity

TOKYO, Feb 8 The Japanese subsidiary of Pfizer Inc is recalling a drug for high blood pressure which was found to contain a carcinogenic substance in its active ingredient valsartan, the drugmaker said on Friday.

08 Feb 2019

Pfizer Japan recalls high blood pressure drug Amvalo due to carcinogen

TOKYO, Feb 8 The Japanese subsidiary of Pfizer Inc is recalling a drug for high blood pressure which was found to contain a substance that can cause cancer, the drugmaker said on Friday.

08 Feb 2019

Swiss stocks - Factors to watch on Feb. 8

ZURICH/BERLIN, Feb 8 The Swiss blue-chip SMI was seen opening 0.2 percent lower at 9.018 points on Friday, according to premarket indications by bank Julius Baer .

08 Feb 2019

BRIEF-Basilea Pharmaceutica: Strong European Cresemba Sales Trigger $5 Mln Milestone Payment

* STRONG EUROPEAN CRESEMBA® (ISAVUCONAZOLE) SALES TRIGGER USD 5 MILLION MILESTONE PAYMENT TO BASILEA FROM PFIZER

08 Feb 2019

Pfizer CEO Bourla plans to testify at Senate drug pricing hearing

NEW YORK, Feb 6 U.S. drugmaker Pfizer Inc said on Wednesday that its Chief Executive Albert Bourla plans to testify later this month at a Senate hearing examining rising prescription drug prices.

06 Feb 2019

Earnings vs. Estimates